Core Laboratories Q2 2025 Earnings Report

Core Laboratories EPS Results

• Actual EPS: $0.19
• Consensus EPS: $0.18
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: $0.22

Core Laboratories Revenue Results

• Actual Revenue: $130.16 million
• Expected Revenue: $129.19 million
• Beat/Miss: Beat by +$969.00 thousand
• YoY Revenue Growth: -0.30%

Core Laboratories Announcement Details

• Quarter: Q2 2025
• Date: 7/23/2025
• Time: After Market Closes
• Conference Call Date: Thursday, July 24, 2025
• Conference Call Time: 8:30AM ET

Core Laboratories (NYSE:CLB) provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies, as well as services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, production, and well abandonment. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. Core Laboratories Inc. was founded in 1936 and is based in Houston, Texas.

Core Laboratories Q2 2025 Earnings Call Transcript

Key Takeaways

• Positive Sentiment: Core Laboratories delivered a strong Q2 performance with revenue up 5% sequentially, operating margins improving 160 bps, and higher free cash flow and EPS.
• Neutral Sentiment: The Reservoir Description segment saw a 7% revenue increase and 13% margins from rebound in fluid analysis and instrument sales, though demand remains uncertain due to geopolitical conflicts and sanctions.
• Positive Sentiment: Production Enhancement revenue rose 3%, margins expanded to 9%, driven by robust U.S. diagnostic services and improved international and domestic completion product sales.
• Positive Sentiment: Balance sheet strength improved as Core repurchased 237,000 shares for $2.7 M, reduced net debt by $9 M, and achieved a leverage ratio at 1.27, an eight-year low.
• Negative Sentiment: Q3 guidance reflects flat to modest revenue growth of $127.5 M to $134.5 M, with near-term spending under pressure from crude price volatility, impending U.S. tariffs, and OPEC+ supply increases.

Presentation

[Operator]

Good day, and welcome to the Core Laboratories Q2 twenty twenty five Earnings Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note, this event is being recorded. I would now like to turn the conference over to Larry Bruno, President. Please go ahead.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

Thanks, Keith. Good morning in The Americas, good afternoon in Europe, Africa and The Middle East, and good evening in Asia Pacific. We'd like to welcome all of our shareholders, analysts and most importantly, our employees to Core Laboratories' second quarter twenty twenty five earnings call. This morning, I'm joined by Chris Hill, Core's Chief Financial Officer and Gwynne Gresham, Core's Senior Vice President and Head of Investor Relations. The call will be divided into six segments.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

Gwen will start by making remarks regarding forward looking statements. We'll then have some opening comments, including a high level review of important factors in Core's Q2 performance. In addition, we'll review Core's strategies and the three financial tenets that the company employs to build long term shareholder value. Chris will then give a detailed financial overview and have additional comments regarding shareholder value. Following Chris, Gwen will provide some comments on the company's outlook and guidance.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

I'll then review Core's two operating segments, detailing our progress and discussing the continued successful introduction and deployment of Core Lab's technologies, as well as highlighting some of Core's operations and major projects worldwide. Then we'll open the phones for a Q and A session. I'll now turn the call over to Gwen for remarks on forward looking statements.

[Gwendolyn Gresham, SVP - IR & Corporate Development at Core Laboratories]

Before we start the conference this morning, I'll mention that some of the statements we make during this call may include projections, estimates, and other forward looking information. This would include any discussion of the company's business outlook. These types of forward looking statements are subject to a number of risks and uncertainties that could cause actual results to materially differ from our forward looking statements. These risks and uncertainties are discussed in our most recent annual report on Form 10 ks as well as other reports and registration statements filed by us with the SEC. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events, or otherwise.

[Gwendolyn Gresham, SVP - IR & Corporate Development at Core Laboratories]

Our comments also include non GAAP financial measures. Reconciliation to the most directly comparable GAAP financial measures is included in the press release announcing our second quarter results. Those non GAAP measures can also be found on our website. With that said, I'll pass the discussion back to Larry.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

Thanks, Gwen. Moving now to some high level comments about our second quarter twenty twenty five results. Core continued to execute its strategic plan of technology investments targeted to both solve client problems and capitalize on Core's technical and geographic opportunities. Second quarter twenty twenty five revenue was up 5% compared to Q1, and Core achieved nice sequential improvement in operating income, operating margins, free cash flow, and earnings per share. Looking at reservoir description in more detail, revenue in the second quarter was up 7% compared to Q1.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

The segment's financial performance in the second quarter reflects continued demand for rocket fluid analysis across the company's global laboratory network, along with a solid quarter of laboratory instrumentation sales. In addition, there was some rebound in the demand for laboratory services tied to the assay of crude oil and derived products as trading patterns partially reset following disruptions caused by enhanced sanctions that were announced on January 10. There is still uncertainty in the demand for these assay services due to ongoing international geopolitical conflicts and sanctions, as well as pending tariffs and the resultant volatility in commodity prices. For the second quarter, ex items, operating margins in Reservoir Description were 13%, up from 10% in Q1. In Production Enhancement, second quarter revenue was up 3% compared to Q1.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

Ex items, second quarter twenty twenty five operating margins were 9%, up from 8% in Q1. This sequential improvement in margins reflects ongoing demand for high margin diagnostic services in The U. S, both onshore and offshore, and improved international and domestic completion product sales. Core Lab returned excess free cash to our shareholders by repurchasing more than 237,000 shares of company stock during the second quarter, a value of $2,700,000 In line with our stated financial strategy, in addition to funding our dividend and repurchasing shares, Core also continued to strengthen its balance sheet. During the second quarter, Core's net debt was reduced by more than $9,000,000 and our leverage ratio now sits at 1.27, its lowest level in eight years.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

Looking forward, intends to use free cash to fund our quarterly dividend, pursue growth opportunities, and improve shareholder value through opportunistic share repurchases while we continue to strengthen our balance sheet. As we look ahead, Coral will continue to execute on its key strategic objectives by: one, introducing new product and service offerings in key geographic markets two, maintaining a lean and focused organization And three, maintaining our commitments to return excess free cash to our shareholders and delevering the company. Now to review Core Lab's strategies and the financial tenants that the company has used to build shareholder value over our nearly thirty year history as a publicly traded company. The interests of our shareholders, clients, and employees will always be well served by Core Lab's resilient culture, which relies on innovation, leveraging technology to solve problems, and dedicated customer service. I'll talk more about some of our latest innovations in the operational review section of this call.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

While we continue to pursue growth opportunities, the company will remain focused on its three long standing, long term financial tenets, those being to maximize free cash flow, maximize return on invested capital, and returning excess free cash to our shareholders. I'll now turn it over to Chris for the detailed financial review.

[Christopher Hill, SVP & CFO at Core Laboratories]

Thanks, Larry. Before we review the financial performance for the quarter, the guidance we gave on our last call and past calls specifically excluded the impact of any FX gains or losses and assumed an effective tax rate of 25%. So accordingly, our discussion today excludes any foreign exchange gain or loss for current and prior periods. Additionally, adjustments which net to a gain of $800,000 have been excluded from today's discussion of the second quarter twenty twenty five financial results. You can find a summary of those items in the tables attached to our press release for the second quarter of twenty twenty five.

[Christopher Hill, SVP & CFO at Core Laboratories]

Looking at the income statement, revenue was $130,200,000 in the second quarter, up $6,600,000 or 5% compared to the prior quarter and flat year over year. Sequentially, the primary drivers were a rebound or restabilization of the maritime movement and trading of crude oil and our associated laboratory assay services, which were disrupted in the first quarter after the expanded sanctions were announced in January. Additionally, we had elevated levels of international product sales for both laboratory instrumentation and completion products when compared to the first quarter. Of this revenue, service revenue, which is more international, was $96,200,000 for the quarter, up 1% sequentially and flat year over year. As mentioned earlier, we saw a nice recovery in our laboratory assay services in the second quarter following the sanctioned driven disruptions in the first quarter.

[Christopher Hill, SVP & CFO at Core Laboratories]

However, this was partially offset by a sequential decrease in our diagnostic services during the second quarter after coming off a five year high in the first quarter. Additionally, the noticeable decrease in success rates over the past twelve months in drilling international offshore exploration and appraisal wells has negatively impacted some of the growth we had anticipated for reservoir rock and fluid analytical programs in 2025. Product sales, which are more equally tied to North America and international activity, were $33,900,000 for the quarter, up 19% sequentially and down slightly year over year. Our international product sales are typically larger bulk orders and can vary from one quarter to another. Sequentially, saw a 25% increase in our international product sales, again driven by increase in bulk shipments and increased laboratory instrumentation sales.

[Christopher Hill, SVP & CFO at Core Laboratories]

Looking at year over year, demand for product sales decreased in The U. S. Onshore market. However, this decline was substantially offset by a higher level of product sales to international markets. Moving on to cost of services ex items for the quarter was 77% of service revenue and comparable to the prior quarter and improved from 78% in the same quarter in the prior year.

[Christopher Hill, SVP & CFO at Core Laboratories]

The year over year and sequential change in cost of services were in line with changes in service revenue. Cost of sales ex items in the second quarter was 85% of revenue and improved compared to 91% last quarter, but up a little compared to 82% last year. The sequential improvement was due to improved manufacturing efficiencies and absorption of fixed costs on a higher revenue base in the quarter. These gains were achieved despite some increase in costs due to elevated tariffs. We anticipate the manufacturing absorption rate in future quarters will be in line with projected product sales.

[Christopher Hill, SVP & CFO at Core Laboratories]

G and A ex items for the quarter was $10,500,000 a slight increase from $10,100,000 in the prior quarter and $10,300,000 in the same quarter of the prior year. For 2025, we expect G and A, ex items, to be approximately $41,000,000 to $43,000,000 Depreciation and amortization for the quarter was $3,700,000 comparable to the last quarter and the same quarter in the prior year. EBIT ex items for the quarter was $14,500,000 up 2,700,000 from $11,800,000 last quarter and yielding an EBIT margin a little over 11% and expanding 160 basis points from last quarter. Our EBIT for the quarter on a GAAP basis was $15,300,000 Interest expense of $2,700,000 increased from $2,600,000 in the prior quarter, but has decreased from $3,200,000 last year due to lower average borrowings on the credit facility compared to last year. Income tax expense and an effective tax rate of 25% and ex items was $3,000,000 for the quarter.

[Christopher Hill, SVP & CFO at Core Laboratories]

On a GAAP basis, we recorded a tax expense of $1,900,000 for the quarter. The second quarter includes the release of a FIN 48 accrual for uncertain tax positions, which decreased income tax expense for the second quarter. The effective tax rate will continue to be somewhat sensitive to the geographic mix of earnings across the globe and the impact of items discrete to each quarter. We continue to project the company's effective tax rate to be approximately 25% for 2025. Net income, ex items, for the quarter was $8,800,000 an increase from $6,700,000 in the prior quarter, but a decrease from $10,400,000 in the second quarter last year.

[Christopher Hill, SVP & CFO at Core Laboratories]

On a GAAP basis, we had net income of $10,600,000 for the quarter. Earnings per diluted share, ex items, was $0.19 for the quarter, an increase from $0.14 in the prior quarter and a decrease from $0.22 last year. On a GAAP basis, EPS was $0.22 for the second quarter of twenty twenty five. Turning to the balance sheet. Receivables were $113,900,000 and decreased approximately $3,100,000 from the prior quarter.

[Christopher Hill, SVP & CFO at Core Laboratories]

Our DSOs for the second quarter improved to 75 days from seventy nine days last quarter. The improvement was primarily driven by the timing of billings and the continued focus on collection efforts during the quarter. Inventory at 06/30/2025, was $59,800,000 slightly up from last quarter end and down approximately $10,100,000 year over year. Inventory turns for the quarter were 1.9, a slight improvement from the prior quarter. With continued focus, we anticipate inventory turns will gradually improve and inventory levels will decline as we progress through the remainder of 2025.

[Christopher Hill, SVP & CFO at Core Laboratories]

And now on the liability side of the balance sheet, our long term debt was $126,000,000 as of 06/30/2025, and considering cash of $31,200,000 net debt was $94,800,000 which decreased 9,100,000 from last quarter end. Our leverage ratio was reduced to 1.27 from 1.31 last quarter end. As of 06/30/2025, our debt was comprised of our senior notes at $110,000,000 and $16,000,000 outstanding under our bank credit facility. Our credit facility has a borrowing capacity of $135,000,000 of which approximately $108,000,000 was still available as of June 30. On 07/22/2025, the company renewed and extended its credit agreement with our corporate bank group.

[Christopher Hill, SVP & CFO at Core Laboratories]

The credit agreement was expanded to include $100,000,000 revolving credit facility, a $50,000,000 delayed draw term loan. The credit agreement also includes an accordion feature to expand the facility by $50,000,000 The term loan component can be accessed until 01/12/2026, and the company plans to use these funds to retire $45,000,000 of private placement notes that mature in January 2026. The renewed credit agreement extends the maturity to 07/22/2029, and there are no significant changes to the terms, including the pricing of variable interest rates on outstanding borrowings. As Larry stated, the company will remain focused on executing its strategic business initiatives while maintaining a healthy balance sheet. Looking at cash flow for the second quarter of twenty twenty five, cash flow from operating activities was approximately $13,900,000 and after paying $3,500,000 of CapEx, our free cash flow for the quarter was $10,400,000 a nice increase from the first quarter.

[Christopher Hill, SVP & CFO at Core Laboratories]

As discussed in prior quarters, the capital expenditures associated with rebuilding our UK facility, which was damaged by fire in February 2024, are covered by the company's property and casualty insurance and have been excluded from the calculation of free cash flow. As we indicated in our last call, we expect CapEx to modestly expand in 2025 compared to 2024, and we will continue to manage investment in working capital. Additionally, we expect CapEx to remain aligned with activity levels, and for the full year 2025, we expect capital expenditures to be in the range of 14,000,000 to $16,000,000 The forecast for capital expenditures excludes the CapEx associated with rebuilding The UK facility that was mentioned earlier. Core will continue its strict capital discipline and asset light business model with capital expenditures primarily targeted at growth opportunities. Core Lab's operational leverage continues to provide the ability to grow revenue and profitability with minimal capital requirements.

[Christopher Hill, SVP & CFO at Core Laboratories]

Capital expenditures have historically ranged from 2.5% to 4% of revenue even during periods of significant growth. That same level of laboratory infrastructure, intellectual property, and leverage exists in the business today. We believe evaluating a company's ability to generate free cash flow and free cash flow yield is an important metric for shareholders when comparing and projecting companies' financial results, particularly for those shareholders who utilize discounted cash flow models to assess valuations. I will now turn it over to Gwen for an update on our guidance and outlook.

[Gwendolyn Gresham, SVP - IR & Corporate Development at Core Laboratories]

Thank you, Chris. Turning to Core Lab's outlook for the third quarter. Recent impending tariffs announced by The U. S. Along with the OPEC plus decision to increase required oil production levels have contributed to additional volatility and uncertainty for crude oil prices.

[Gwendolyn Gresham, SVP - IR & Corporate Development at Core Laboratories]

Uncertainty surrounding crude oil demand driven in part by ongoing trade negotiations and macroeconomic concerns coupled with OPEC plus increasing required production levels has prompted prompted oil and gas companies to reevaluate their near term upstream spending priorities. Despite near term volatility, Core Lab maintains a constructive long term outlook for international upstream activity. The IEA, EIA, and OPEC plus continue to forecast global crude oil demand growth ranging from 700,000 to 1,300,000 barrels per day for 02/2025. This growth continues to be driven primarily by demand from the non OECD countries, including Asia, India, and emerging markets across The Middle East and Africa. Outside The US, large scale international oil and gas projects are expected to be less sensitive to near term volatility of crude oil prices.

[Gwendolyn Gresham, SVP - IR & Corporate Development at Core Laboratories]

Encore Labs sees steady activity across committed long cycle investments in the South Atlantic margin, North And West Africa, Norway, The Middle East, and certain areas of Asia Pacific. And CORE views these developments as stable contributors to global activity levels. These projects, by nature of their scale and planning cycles, tend to be less attractive to near term reactive to near term commodity price fluctuations. As always, Core Lab's revenue opportunity on awarded projects will remain dependent on our clients' geological success rates. In contrast, US onshore activity levels tied to small scale short cycle crude oil development projects remains more sensitive to crude oil price volatility.

[Gwendolyn Gresham, SVP - IR & Corporate Development at Core Laboratories]

As a result, Core Lab anticipates that changes in crude oil prices will have a more immediate and pronounced impact on drilling and completion activity across The US onshore market. Core projects Reservoir Description's third quarter revenue to be flat sequentially. Geopolitical conflict, evolving trade and tariff dynamics, and volatile commodity prices continue to create uncertainty in the demand for laboratory services tied to the maritime transportation and trade of crude oil and derived products. Turning to production enhancement. The US frac spread count continues to trend lower and the company anticipates a soft market for the remainder of the year.

[Gwendolyn Gresham, SVP - IR & Corporate Development at Core Laboratories]

However, growth in demand for Core's international and offshore diagnostic services and energetic system product sales are anticipated to offset declines in US onshore activity. The company believes that tariff measures under consideration will not apply to the vast majority of service revenue and product sales provided by Core Lab. Core's services account for over 75% of its total revenue and are currently not subject to tariffs. The company's product sales have been less than 25% of total revenue and are primarily manufactured in The US. Import tariffs would not apply to approximately 50% of these products as they are consumed in The US drilling and completion market.

[Gwendolyn Gresham, SVP - IR & Corporate Development at Core Laboratories]

Certain raw materials imported and used in production enhancements US manufacturing of products are attracting import tariffs. CORE is currently taking steps to mitigate the impact of tariffs. In summary, Reservoir Description's third quarter revenue is projected to range from 84,000,000 to 88,000,000 and operating income of 10,600,000.0 to 12,400,000.0. Production enhancements third quarter revenue is estimated to range from 43,500,000.0 to 46,500,000.0, with operating income of 2,900,000.0 to 3,700,000.0. Core's third quarter twenty twenty five revenue is projected to range from 127,500,000.0 to 134,500,000.0 with operating income of 13,600,000.0 to 16,200,000.0, yielding operating margins of 11%.

[Gwendolyn Gresham, SVP - IR & Corporate Development at Core Laboratories]

EPS for the third quarter is expected to range from 18¢ to 22¢. The company's third quarter guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange. Core's third quarter guidance assumes an effective tax rate of 25%. With that, I will turn the call back over to Larry.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

Thanks, Gwen. First, I'd like to thank our global team of employees for providing innovative solutions, integrity, and superior service to our clients. The team's collective dedication to servicing our clients is the foundation of Core Lab's success. Looking at the macro, even after assessing current and near term economic conditions, IEA, EIA, and OPEC projections show that there will be growth in global crude oil demand in 2025 and beyond. The various estimates show growth in demand of between zero point seven and one point three million barrels per day for 2025, with similar additional demand growth projected for 2026.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

This growth is driven mainly by strong non OECD demand, including Asia, India, emerging markets in The Middle East and Africa. In addition to the forecasted growth in demand, new production will need to be brought online to account for the natural decline from existing producing fields. Combined, these trends will require continued investment in the development of onshore and offshore crude oil fields. Furthermore, the most recent EIA forecast for US oil production is 13,400,000 barrels per day in 2025, and the agency currently projects production to remain at the same level in 2026, with little or no growth in US production over this timeframe. Aside from the COVID period and the transitory market reset in 2016, these forecasts for nominal year over year production growth would suggest the smallest annual adds to U.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

S. Oil production in the past fifteen years. U. S. Tight oil production has been by far the largest component of non OPEC oil production growth since 2010.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

Continued growth in global oil demand combined with slowing year over year U. S. Oil production growth supports the thesis that future crude oil demand will be largely met from international, conventional, offshore discoveries and developments, all trends that bode well for increasing demand for the reservoir description services that we provide through our global lab network. We project this international cycle will play out for the next several years and perhaps longer as the growth in U. S.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

Land production continues to decline. Production enhancement, in addition to its exposure to The U. S. Land market, also has expanding opportunities across international markets such as with unconventional plays in The Middle East and emerging onshore and offshore conventional plays in a number of regions. Burlab also continues to expand its portfolio of innovative offerings for perforating applications, plug and abandonment operations and completion diagnostics for our growing global client base.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

Now let's review the second quarter performance of our two business segments. Turning first to Reservoir Description. For the second quarter of twenty twenty five, revenue came in at $86,300,000 up 7% compared to Q1. For Q2, operating income for Reservoir Description ex items was $10,800,000 up from $7,800,000 in Q1, yielding operating margins of 13% and incremental margins of 57%. While demand for reservoir description lab services remained strong in several regions across our global network, ongoing international geopolitical conflicts, along with expanded sanctions that were enacted in early Q1, continue to produce headwinds that impacted demand for laboratory services tied to the trade and transportation of crude oil and derived products.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

The demand for these services did rebound some in the second quarter as trading patterns continue to realign. Now for some operational highlights from Reservoir Description. Despite Columbia instituting restrictions on new exploration programs, Core Lab continued to engage on new projects during the second quarter. Has expanded its technical support for the country's national energy sustainability efforts by engaging in both enhanced oil recovery and carbon capture and storage projects. Core Lab is providing essential laboratory services for a project in the Eastern Lanos Basin where Columbia's most critical in situ combustion enhanced oil recovery initiative is underway.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

The analytical measurements Core provided serve as the foundation for data driven decisions that are key to understanding how to best unlock up to a billion barrels of recoverable heavy oil. While the in situ combustion process efficiently boosts production by reducing oil viscosity and improving flow, it also generates significant volumes of CO2 from the production wells that must be either sequestered in the subsurface or re injected into oil bearing zones as part of a companion EOR program. Korolev's Bogota laboratory is using its proprietary PVT technology to assess CO2 phase behavior and the interaction of CO2 with other subsurface pore fluids. This high accuracy testing is vital for validating the technical feasibility of CO2 sequestration and utilization opportunities in Columbia's heavy oil fields. Around the globe, Core Lab remains a critical partner in maximizing oil production from challenging mature fields.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

Moving now to production enhancement, where Core Lab's technologies continue to help our clients optimize their well completions and improve production. Revenue for Production Enhancement for Q2 came in at $43,900,000 up 3% compared to Q1. Second quarter operating income for Production Enhancement, ex items, was $3,100,000 yielding operating margins of 9%, up from 8% in Q1. In The U. S, diagnostic services benefited from increased demand as complex U.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

S. Land completion designs like trimal fracs become more and more common. SCOR's expansive portfolio of completion products also saw increased demand in both international and domestic markets. Now for some operational highlights from Production Enhancement. During the second quarter of twenty twenty five, following a competitive evaluation of shaped charge performance, Core Lab secured a project with two major international E and P operators doing business in Canada.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

The client sought an energetic solution capable of delivering the most consistent perforating results for unconventional reservoir completions in their upcoming campaign. Using third party downhole imaging technology to verify the performance of multiple competing technologies, the client confirmed that Core's proprietary HERO Perfract perforating system outperformed the competition, earning the top rank due to its exceptionally consistent hole size and repeatable performance. The operators have now specified that Core Lab's proprietary charge will be used on their upcoming completion activities moving forward. Core's Hero Per Frac Energetic technology is engineered with advanced design protocols and under strict quality control and continues to distinguish itself as a preferred solution for onshore unconventional frac operations. Also in Q2, Core Lab continued to expand its engagement on geothermal energy projects across North America through the deployment of its proprietary thermal profiler tracers.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

This advanced technology utilizes Core's select portfolio of tracers that provide extreme thermal stability, even for applications where temperatures exceed 500 degrees Fahrenheit. Core Lab's Thermal Profiler tracers are being used to map the flow pattern of water injected into high temperature subsurface geothermal structures. Unlike other tracers which degrade under such extreme conditions, CORE's suite of thermal profiler tracers maintain their integrity at high temperatures. This capability is critical to optimizing geothermal project performance, particularly in hot, complex, frequently fractured igneous and metamorphic rock formations. Core Lab has successfully deployed its thermal profiler diagnostic tracer technology in multiple geothermal projects and is actively engaged in discussions with additional geothermal operators regarding future deployments.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

That concludes our operational review. We appreciate your participation, and Keith will now open the call for questions.

[Operator]

Yes. Thank you. We will now begin the question and answer And the first question comes from Sean Mitchell with Daniel Energy Partners.

[Sean Mitchell, Managing Partner at Daniel Energy Partners]

Hey, Larry. Thanks for taking my question. Any additional color around the kind of new proppant design that you've kind of partnered with the West Texas operator in the quarter? Is that really above and beyond? Is really a new proppant design?

[Sean Mitchell, Managing Partner at Daniel Energy Partners]

Or is that a frac design? Or can you talk a little bit more about that?

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

Yes. So our engagement on that was less about the design of the proppant in this particular case, although we do engage in those types of analyses through our STEM lab operation. Our engagement was about them trying different designs of the proppant sort of particle size and the sorting, if you will, or uniformity of particles, and then putting tracers in to alternating zones, testing sort of, their existing croppant configuration versus the new one they were trialing. And, with the tracer flowback, we were able to confirm that the new design was, producing better results from those intervals that deployed the revised design of the proppant particle size and sorting.

[Sean Mitchell, Managing Partner at Daniel Energy Partners]

Okay. That's helpful. That's good color. And then anything else on the new product or kind of service offering side? I know you guys are constantly coming up with new ideas that you're super excited about maybe over the next kind of twelve to eighteen months, in particular in The Middle East.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

Yeah, I mean, one other thing, going back on that, to the Proppant deal, I think it's an important thing to understand about our diagnostic services. As people try new technology, they and just conceptualize this, think about a well with a three mile lateral, you're 15,000 feet from the surface, you're trying to figure out, in a hole 10 inches around or less, did I execute the completion the way I wanted or as I change and modify completions, am I getting the desired results? And the diagnostic tracers really unravel that. So we've got a number of technologies on both sides of the business. I'd say one that we're really focused on is formation damage.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

We've made quite an initiative into looking at ways of laboratory testing formation damage as people are introducing various different completion fluids into the well. How's that reacting with the rock and with the fluids? So that would be something that we've made investments in The Middle East in particular. Another one in large scale that we did, and Gwen and I were over earlier in the second quarter, we opened up our unconventional laboratory in Dammam, Saudi Arabia. So we do see that there are, I'd say, growing opportunities into a game that's in the early innings of unconventional resource development throughout the region.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

And so we've taken a lot of the proprietary technologies that we've developed for dealing with the unconventional reservoirs in North America, and we've now replicated that equipment and those techniques and technologies, and we brought that into Saudi Arabia. We've always had a great partnership with, Saudi Aramco, and we think that we can service them and others, in the region as unconventionals grow along the Arabian Peninsula.

[Sean Mitchell, Managing Partner at Daniel Energy Partners]

Got it. That's very helpful. I appreciate the color. I'll turn it back.

[Gwendolyn Gresham, SVP - IR & Corporate Development at Core Laboratories]

Thanks, Sean.

[Operator]

Thank you. Right. Is there nothing else at the present time? I would like to return the floor to Larry Bruno for any closing comments.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

Okay. Yeah, think we've got kind of a busy morning of, earnings releases coming out, so we'll wrap up here. In summary, Core's operational leadership continues to position the company for improving client activity levels in the upcoming quarters. We have never been better operationally or technologically positioned to help our global client base optimize their reservoirs and to address their evolving needs. We remain uniquely focused and are the most technologically advanced client focused reservoir optimization company in the oilfield service sector.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

The company will remain focused on maximizing free cash and returns on invested capital. In addition to our quarterly dividend, we'll bring value to our shareholders via opportunistic through opportunities driven by both the introduction of problem solving technologies and new market penetration. In the near term, Core will continue to use free cash to repurchase shares and strengthen its balance sheet while always investing in growth opportunities and evaluating various methods to increase shareholder value. So in closing, we thank and appreciate all of our shareholders and the analysts that cover Core Lab. The executive management team and the board of Core Laboratories give a special thanks to our worldwide employees that have made these results possible.

[Lawrence Bruno, Chairman, President & CEO at Core Laboratories]

We're proud to be associated with their continuing achievements. So thanks for spending time with us, and we look forward to our next update. Goodbye for now.

[Operator]

Thank you. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect your lines.

Participants

Executives

• Lawrence Bruno, Chairman, President & CEO
• Gwendolyn Gresham, SVP - IR & Corporate Development
• Christopher Hill, SVP & CFO

Analysts

• Sean Mitchell, Managing Partner at Daniel Energy Partners